Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Past Secrets for the Future of Lupus

David S. Pisetsky, MD, PhD  |  Issue: August 2011  |  August 1, 2011

So, to my fellow limo rider with a storied hard-court past, thank you for telling us about your exploits as an athlete. I looked you up on PubMed and think that you are certainly in the top 10 in a state filled with some of the best lupologists in the world. You are making fine progress. Be aware that the rewards of sports and medicine are different. In our profession, there are no autograph seekers or paparazzi, no dopey interviews with the media (“Tell us, Dr. M., what was going through your mind when you presented the data on safety?”), no appearance money, and no endorsement contracts from Avon, Reebok, or Gatorade—the Williams sisters and Maria Sharapova (who is lithe and lissome, by the way) have that business sewn up.

As you continue to do research and advance in your academic career, Dr. M., please use the lessons you learned playing tennis: Work hard, keep your eye on the ball, and follow through.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Good luck. And, for the patients with lupus who need your help, I hope that you hit real winners.

Dr. Pisetsky is physician editor of The Rheumatologist and professor of medicine and immunology at Duke University Medical Center in Durham, N.C.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:ConditionsOpinionRheuminationsSpeak Out RheumSystemic Lupus Erythematosus Tagged with:DrugsLupusLupus nephritisMeetingsystemic lupus erythematous

Related Articles

    Dr. Guillermo Valenzuela: Truffle Hunter, Tennis Player, Motorcycle Tourist

    June 17, 2019

    Some would call Guillermo J. Valenzuela, MD, a hunter of sorts. He has accompanied men and their dogs into the forests of Italy in search of white truffles, an underground fungus considered a European delicacy. “Years ago, when visiting my wife’s family in Italy, I walked into a very old restaurant in Parma,” says Dr….

    Belimumab Promising for Children with Lupus Nephritis

    October 6, 2022

    Belimumab is now FDA approved to treat children aged 5 years and older with active lupus nephritis, providing treatment options for pediatric patients at risk of developing renal damage.

    The Great Debate: Belimumab vs. Voclosporin in Lupus Nephritis

    December 1, 2021

    ACR Convergence 2021—The Great Debate at the meeting sparked a thoughtful discussion on the future of lupus nephritis treatment strategies, with experts saying clinicians should be open to new ways of approaching patient care. In the past year, approvals of the monoclonal antibody belimumab and the calcineurin inhibitor voclosporin for use in lupus nephritis (when…

    Mitigate Risk and Increase Success of Lupus Clinical Trials

    August 1, 2010

    Design strategies from a Lupus Research Institute conference

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences